Parker Institute for Cancer Immunotherapy
13
216M
8
1.62
2
0.38
- Areas of investment
Summary
Parker Institute for Cancer Immunotherapy appeared to be the Corporate Investor, which was created in 2016. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the San Francisco.
Among the most popular portfolio startups of the fund, we may highlight ArsenalBio, ImaginAb. The fund has no specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Health Care, Biotechnology.
The current fund was established by Sean Parker.
The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Parker Institute for Cancer Immunotherapy, startups are often financed by Penn Medicine Co-Investment Fund, Novartis Venture Fund, Lilly Asia Ventures. The meaningful sponsors for the fund in investment in the same round are Ping An Ventures, Penn Medicine Co-Investment Fund, Lilly Asia Ventures. In the next rounds fund is usually obtained by Penn Medicine Co-Investment Fund, Lilly Asia Ventures, Gilead Sciences.
Investments analytics
Analytics
- Total investments
- 13
- Lead investments
- 2
- Rounds per year
- 1.62
- Follow on index
- 0.38
- Investments by industry
- Biotechnology (11)
- Health Care (9)
- Therapeutics (8)
- Genetics (3)
- Manufacturing (3) Show 8 more
- Investments by region
-
- United States (11)
- United Kingdom (2)
- Peak activity year
- 2023
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Xaira Therapeutics | 23 Apr 2024 | Early Stage Venture | 1B | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.